Zenas BioPharma, Inc.
ZBIO Nasdaq
SEC CIK 1953926
Follow Zenas BioPharma
Weekly email: filings, results
Revenue, last quarter
$10M
Net income
−$108.9M
−111.5% vs same quarter last year
EPS, diluted
−$1.65
−35.2% vs same quarter last year
Operating cash flow
−$58M
−41% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $10M | −$377.7M |
| FY24 | $5M | −$157M |
| FY23 | $50M | −$37.1M |
| FY22 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −3830.6% | −3777.4% |
| FY24 | −3277.8% | −3139.8% |
| FY23 | −74.3% | −74.2% |
| FY22 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$172.4M |
| FY24 | −$119.8M |
| FY23 | −$30.5M |
| FY22 | - |
- Zenas BioPharma
- Healthcare median
Show the numbers
| Year | Zenas BioPharma | Healthcare median |
|---|---|---|
| FY25 | −3777.4% | −30.6% |
| FY24 | −3139.8% | −47% |
| FY23 | −74.2% | −58% |
| FY22 | - | −80.4% |